Compare BridgeBio Pharma Inc (BBIO) vs ProShares Ultra Bitcoin ETF (BITU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ProShares Ultra Bitcoin ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while ProShares Ultra Bitcoin ETF trades at $9.2. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | BITU | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $64.41 |
52-Week Low | $47.29 | $8.12 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
BITU trades at $9.64, up 1.69% with neutral technical signals. The stock shows mixed momentum with bullish moving averages but neutral oscillators. Recent dividend payments of $0.01-$0.02 provide shareholder returns, though key financial ratios remain undisclosed in current filings.
The outlook remains cautious with technical indicators showing limited directional bias. Investment opportunity exists through dividend yield, but risks include volatility and lack of clear fundamental data. Analyst sentiment appears neutral with equal buy/sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →
